(VIANEWS) - Old Second Bancorp (OSBC), Neurocrine Biosciences (NBIX), Ares Commercial Real Estate Corporation (ACRE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Old Second Bancorp (OSBC)
41.2% sales growth and 9.2% return on equity
Old Second Bancorp, Inc. is the bank holding firm for Old Second National Bank. It provides community banking services. The bank offers checking, certificate of deposit and demand, NOW money market, savings time deposit, retirement planning, personal retirement plans, and saving. It also provides commercial loans and lease financing receivables, construction loans and residential real estate loans such as residential first and second mortgage loans. Home equity lines of credit, consumer loans including signature, motor vehicle and home improvements loans and installment loans. Residential mortgages are available. Overdraft checking is an option. It also offers safe deposit services, trust and wealth management, money orders, cashier’s checks, foreign currencies, direct deposits and discount brokerage. Debit and credit cards are available as well as acquiring U.S. Treasury notes and bonds. The company also offers mobile and online banking. It provides corporate cash management services, such as remote deposits capture and zero balance accounts. Automated tax payments are made through automatic teller machines. Telephone banking is available. Lockbox accounts and automated clearinghouse transactions can be used. Account reconciliations, detailed and general information reporting and account reconciliations, controlled disbursement, wire transfer details and reports, vault services and custodial service for individuals, corporations, and non-profits. The company operates out of 63 banks in Cook, DeKalb and DuPage counties, Kane, Kendalls, LaSalle, Will, and Kane. Old Second Bancorp, Inc., was established in 1981. It is located in Aurora, Illinois.
Earnings Per Share
As for profitability, Old Second Bancorp has a trailing twelve months EPS of $0.63.
PE Ratio
Old Second Bancorp has a trailing twelve months price to earnings ratio of 24.24. Meaning, the purchaser of the share is investing $24.24 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.2%.Moving Average
Old Second Bancorp is at $16.73 below its 50-day moving mean and $14.86 above its 200 day moving average.Growth Estimates Quarters
The company's growth estimates for the current quarter and the next is 41.7% and 81.5%, respectively.Revenue Growth
Year-on-year quarterly revenue growth grew by 87%, now sitting on 198.18M for the twelve trailing months.
Dividend Yield
Morningstar, Inc. claims that the next dividend payment will be on January 25, 2023. The forward dividend rate and forward dividend yield are 0.25% and 1.31%, respectively.
2. Neurocrine Biosciences (NBIX)
28.5% sales growth and 4.03% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $0.61.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 182.56. Meaning, the purchaser of the share is investing $182.56 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.03%.Revenue Growth
Year-on-year quarterly revenue growth grew by 31%, now sitting on 1.39B for the twelve trailing months.
Sales Growth
Neurocrine Biosciences has experienced a 30.5% increase in sales for its current quarter, and a 28.5% growth for the next.
Earnings before Interest, Taxes and Depreciation
Neurocrine Biosciences EBITDA stands at 95.32
Growth Estimates Quarters
The company's growth estimates for the present quarter and the next is 1512.5% and 471.4%, respectively.3. Ares Commercial Real Estate Corporation (ACRE)
25.1% sales growth and 6.12% return on equity
Ares Commercial Real Estate Corporation is a special finance firm that invests in and originates commercial real estate loans in the United States. The company offers a variety of financing options for CRE property owners and operators. It originates subordinate and senior mortgage products as well as mezzanine, mezzanine, and other CRE investment, such commercial mortgage-backed securities, mortgage-backed securities, mortgage preferred equity investments, mortgage preferred equity investments, mortgage preferred equity investments, real estate prefered equity investments, and others. Ares Commercial Real Estate Corporation is qualified and has chosen to be taxed under the Internal Revenue Code of 1986 as a real property investment trust. As the company's manager, Ares Commercial Real Estate Management LLC is responsible. It was established in New York in 2011.
Earnings per Share
Ares Commercial Real Estate Corporation's trailing twelve-month EPS is $0.89.
PE Ratio
Ares Commercial Real Estate Corporation's trailing 12-month price-to-earnings ratio is 12.43. The purchaser of the shares is purchasing $12.43 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 6.12%.Moving Average
Ares Commercial Real Estate Corporation's worth is below its 50-day moving average of $11.57 and way under its 200-day moving average of $12.97.4. Five Below (FIVE)
8.2% sales growth and 22.03% return on equity
Five Below, Inc. is a US specialty value retailer. Accessories include socks, accessories such as jewelry, scarfs, gloves and hair accessories. It also offers sport balls, team merchandise, fitness accessories such as jump ropes and hand weights; as well as toys that cover remote control, pool, beach and outdoor, the company sells games and accessories. It also offers accessories for smartphones, tablets, and audio devices, including cases, chargers and headphones; books and video games; DVDs; crafts and craft supplies such as markers, crayons and stickers; trend-right school items such as backpacks, notebooks, journals and novelty pens, pencils, locker accessories and daily name brand products. The company also offers party supplies, decorations, gag presents, and greeting cards. It has a variety of candy bars (both classic and novelty), movie-sized box candy, seasonal candy, gum, snack food, chilled beverages through coolers, and items that are used to decorate and celebrate events. The company primarily caters to teen and teenage customers. The company had approximately 1190 locations in 40 states as of the 29th of January 2022. The original name of the company was Cheap Holdings, Inc., but it changed its name in August 2002 to Five Below, Inc. Five Below, Inc. was founded in 2002. It is located in Philadelphia, Pennsylvania.
Earnings Per Share
As for profitability, Five Below has a trailing twelve months EPS of $2.2.
PE Ratio
Five Below has a trailing twelve months price to earnings ratio of 84.16. Meaning, the purchaser of the share is investing $84.16 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.03%.